IFPMA Facts and Figures Report
Related news and resources
158th session of the WHO Executive Board (EB158): Priorities for financing noncommunicable diseases to achieve universal health coverage
On 2 February 2026, PATH delivered a joint constituency statement on Agenda itea 6: Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases at the 158th session of the WHO Executive Board. Sustainable and responsible financing—powered by multisectoral collaboration—is key to meet the...
Read moreThe innovation development and access pathway: A holistic approach to accelerating access to innovative medicines and vaccines
IFPMA introduces the “Innovation Development and Access Pathway” (IDAP), a framework designed to build a shared understanding of the end-to-end pathway of how medicines and vaccines move from discovery to delivery at the point of care. The paper maps the four critical pillars of this journey: R&D and the innovation ecosystem; regulatory processes and life cycle management; listing, procurement and reimbursement; and health service delivery. It identifies systemic challenges, and proposes collaborative solutions to overcome them, and shows that improving access requires coordinated action across stakeholders, with governments playing a central role in enabling timely and equitable access to innovation.
Read more
WIPO Standing Committee on Patents (SCP 37): Patents and health
On 4 November 2025, IFPMA delivered a statement on patents and health at the WIPO Standing Committee on Patents (SCP 37) in Geneva. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents the global research-based biopharmaceutical industry. We appreciate the opportunity to address the Committee on patents and health. Intellectual property is fundamental to...
Read more